Latest California Healthline Stories
Despite Insurers’ Tactical Win On ACA’s Cost-Sharing Payments, Uncertainty Lingers
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Covered California Expects 12.5% Average Rate Rise In 2018
The figure could be higher if President Trump ends an important consumer subsidy, which he has threatened to do. Anthem Blue Cross will pull out of the exchange and the overall individual market in 16 of 19 regions in the state.
Denial, Appeal, Approval … An Adult’s Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Little-Known Middlemen Save Money On Medicines — But Maybe Not For You
Kaiser Health News examines the role of PBMs in the prescription drug-pricing pipeline.
Drug Puts A $750,000 ‘Price Tag On Life’
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Whistleblowers: United Healthcare Hid Complaints About Medicare Advantage
A Wisconsin lawsuit alleges United Healthcare downplayed abusive sales tactics to avoid losing government bonuses.
Want To Know Your Hospital’s C-Section Rate? Yelp Is On The Way.
The review site aims to help women make better-informed choices about where to deliver their babies.
Scope Maker Olympus Hit With $6.6 Million Verdict In Superbug Outbreak Case
In the first case of its kind in the U.S., the company was ordered to pay damages to the hospital where a patient died of an infection linked to a contaminated scope. But jurors also found the hospital negligent, and it was ordered to pay the patients’ family $1 million.
Over-The-Counter Devices Hold Their Own Against Costly Hearing Aids
In a head-to-head comparison, several of the cheaper devices performed nearly as well as the expensive hearing aids. The study lends credence to lawmakers’ efforts to get the FDA to set standards for the “personal sound amplification products.”
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.